Shilpa Medicare secures DRDO nod for manufacturing anti-COVID drug 2DG

Karnataka: Shilpa Medicare Limited, has recently announced that the company has received an in-principle approval from Defence Research & Development Organisation (DRDO) to manufacture and sale of 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for COVID-19 patients in the country.

"Shilpa Medicare Limited is only the second company in India to have entered into similar arrangement with DRDO," the company said in a filing.

Shilpa has been continuously striving to contribute towards the fight against COVID-19 and this is yet another step by Shilpa after its recently announced arrangement for manufacture and supply of Sputnik V vaccine, the drugmaker added.

Read also: Dr Reddys, Shilpa Medicare ink agreement for Sputnik V production